| Description | This product 8H12 is a mouse neutralizing antibody binding SARS-CoV-2 Spike S1. It binds to the left shoulder of the RBD and it has high binding affinity against spike proteins of the variants. 8H12 shows diverse neutralizing breadths against the SARS-CoV-2 variants. It could neutralize all variants that emerged before BA.4/5. |
| Clonality | Monoclonal |
| Host Species | Mouse |
| Target Species | SARS-CoV-2 |
| Cross Reactivity | WT, Alpha, Beta, Gamma, Delta, Omicron |
| Immunogen | Recombinant spike proteins (S2P) of SARS-CoV-2 and SARS-CoV |
| Epitope | The epitope of 8H12 is composed of RBD residues (K417, L455, F456, Y473, A475, G476, S477, V483, E484, G485, F486, N487, F489, and Q493) mainly focused on the 472-489 loop. |
| IC50 | 34 ng/mL (D614G) 41 ng/mL (Alpha B1.1.7) 78 ng/mL (Beta B1.1.351) 92 ng/mL (Gamma P.1) 51 ng/mL (Delta B.1.617.2) 163 ng/mL (Omicron BA.1) |
| Affinity | KD = 0.40 nmol/L (WA-RBD) KD = 2.23 nmol/L (B.1.1.7-RBD) KD = 1.5 nmol/L (B.1.351-RBD) KD = 3.76 nmol/L (B.1.617.2-RBD) KD = 4.39 nmol/L (BA.1-RBD) KD = 7.27 nmol/L (BA.2-RBD) KD = 5.24 nmol/L (BA.2.12.1-RBD) KD = 2.31 nmol/L (BA.2.75-RBD) KD>300 nmol/L (BA.4/5-RBD) KD = 0.87 nmol/L (WT-S6P) KD = 3.08 nmol/L (BA.1-S6P) KD = 6.81 nmol/L (BA.2-S6P) KD = 1.14 nmol/L (BA.2.75-S6P) KD>300 nmol/L (BA.4/5-S6P) |
| Isotype | Mouse IgG1 |
| Expression Species | HEK293F or CHO cell line |
| Conjugation | Unconjugated |
| Purity | >95% |
| Endotoxin | <1 EU/mg |
| Form | Liquid |
| Purification | Protein G purified |
| Sterility | 0.2 μM filtered |
| Formulation | PBS, pH 7.4 |
| Preservation | No preservatives |
| Stabilizer | No stabilizers |
| Storage | Store at 4°C within one or two weeks. Store at -20°C for long term. Avoid repeated freeze/thaw cycles. Refer to the COA file for specifics. |
| Application | ELISA; SPR; Neut; FRNT |
| Application Notes | This antibody was tested using ELISA, Surface plasmon resonance (SPR) and Neutralization assay. ELISA: Plates were blocked with ELISA-blocking buffer and then incubated with 3-fold serially diluted antibodies diluted from a starting concentration of 10 µg/mL for 1 h at 37°C. Surface plasmon resonance (SPR): Serially diluted antibodies (800, 400, 200, 100, 50, 25, 12.5, and 6.25 nmol/L) then flowed through the sensor surface at a flow rate of 30 µL/min in PBS-P+ buffer. Neutralization assay (Neut): Serial dilutions of tested antibodies were mixed with 50 µL of virus (100 focus forming units) in 96-well microwell plates and incubated at 37°C for 1 h. |
| ELISA | Enzyme-Linked Immunosorbent Assay Protocol |
| WB | Western Blot Protocol |
| FC | Flow Cytometry Protocol |
| Target | SARS-CoV-2 S1 |
| Alternative Name | Severe acute respiratory syndrome coronavirus 2 Spike S1 |
| Research Area | Coronavirus Disease 2019 |
| Related Disease | Coronavirus Disease 2019 |
